Delivering next-generation, game-changing immune-oncology therapies to patients living with cancer

ABOUT US

ABOUT US

Our mission is to leverage state-of-the-art technology, our oncology expertise and extensive R&D experience to develop and grow a diversified portfolio of next-generation, game-changing cancer immunotherapies.

Our home is in Zug, Switzerland, our minds are on the art of oncology drug development, and our hearts are with patients living with cancer.

We are Laevoroc Oncology.

PIPELINE

Our pipeline is housed within two independent subsidiaries.

Developing different assets within contained subsidiaries means they can proceed independently and we can make independent financing and licensing/sales agreements. We see this as an important way to make the company more resilient, and better align with the interests of potential partners, and ultimately patients.

Our portfolio consists of state-of-the-art immune-oncology assets with the potential to transform treatment outcomes for medically underserved haematological malignancies and become game-changers in a wider range of applications. As an extension of our commitment to deliver game-changing cancer therapies, we have entered into a joint venture with the purpose to deliver urgent and impactful chemotherapeutics that significantly improve health equity and quality of care for cancer patients around the world.

laevoroc-immunology

Laevoroc Immunology

is progressing LR 09 (a highly potent and selective PNP inhibitor). With LR 09 we are developing a novel molecule to guide the immune system by receptor activation to eradicate relapsed leukemia after allogeneic stem cell transplantation. Our vision is to enable the cure of this disease, which is catastrophic medically after relapse. Relapse post transplantation is the most frequent cause of treatment failure, in children and adults. Our innovation is a game-changing new therapy with the potential to become standard of care.

space

Laevoroc Chemotherapy

a joint venture with Lipomed AG, is progressing LR 06B (a patented oral gemcitabine prodrug for maintenance therapy in pancreatic, ovarian and breast cancers). Intersecting cutting-edge medicinal chemistry and formulation technology, LR 06B is rationally designed to release gemcitabine in the liver after first-pass metabolism. The innovation of our new molecule for oral administration aims to deliver a cancer therapy that provides a low healthcare system and patient burden, while allowing entirely new uses of gemcitabine, including combination therapy with oral targeted agents such as PARP inhibitors.

PIPELINE

Our pipeline is housed within two independent subsidiaries.

Developing different assets within contained subsidiaries means they can proceed independently and we can make independent financing and licensing/sales agreements. We see this as an important way to make the company more resilient, and better align with the interests of potential partners, and ultimately patients.

Our portfolio consists of state-of-the-art immune-oncology assets with the potential to transform treatment outcomes for medically underserved haematological malignancies and become game-changers in a wider range of applications. As an extension of our commitment to deliver game-changing cancer therapies, we have entered into a joint venture with the purpose to deliver urgent and impactful chemotherapeutics that significantly improve health equity and quality of care for cancer patients around the world.

space

Laevoroc Chemotherapy

is progressing LR 06 (a patented oral gemcitabine prodrug for maintenance therapy in pancreatic, ovarian and breast cancers). With LR 06 we are reimagining the use of one of the most important chemotherapy agents worldwide, gemcitabine, by developing a unique, patented, oral prodrug form to create differentiated uses. The innovation of rationally designing a new molecule for oral administration is about providing a cancer therapy that provides a low healthcare system burden, and a low patient burden.

space

Laevoroc Chemotherapy

is progressing LR 06 (a patented oral gemcitabine prodrug for maintenance therapy in pancreatic, ovarian and breast cancers). With LR06 we are reimagining the use of one of the most important chemotherapy agents worldwide, gemcitabine, by developing a unique, patented, oral prodrug form to create differentiated uses. The innovation of rationally designing a new molecule for oral administration is about providing a cancer therapy that provides a low healthcare system burden, and a low patient burden.

microscope

Laevoroc Immunology

is progressing LR 09 (a highly potent and selective PNP inhibitor). With LR 09 we are developing a novel molecule to guide the immune system by receptor activation to eradicate relapsed leukemia after allogeneic stem cell transplantation. Our vision is to enable the cure of this disease, which is catastrophic medically after relapse. Relapse post transplantation is the most frequent cause of treatment failure, in children and adults. Our innovation is a game-changing new therapy with the potential to become standard of care.

Microscopic image

Laevoroc Immunology


is progressing LR09 (a highly potent and selective PNP inhibitor). With LR09 we are developing a novel molecule to guide the immune system by receptor activation to eradicate relapsed leukemia after allogeneic stem cell transplantation. Our vision is to enable the cure of this disease, which is catastrophic medically after relapse. Relapse post transplantation is the most frequent cause of treatment failure, in children and adults, and our innovation is a game-changing new form of therapy with the potential to become standard of care.

brain

Laevoroc Neuro-Oncology

is the core of our company and will build a pipeline of innovative drugs addressing brain cancers. Right now, we are progressing LR 02 (a highly selective and potent ATR inhibitor with outstanding CNS penetration). With LR 02 we are introducing a highly innovative therapeutic principle to beating brain cancer with a new mode of action based on synthetic lethality. Brain tumors are among the most difficult to treat and most feared forms of cancer, and it is a disease with a dismal survival rate: the average is just 15 months.

shutterstock_1809283648

Laevoroc Neuro-Oncology

is the core of our company and will build a pipeline of innovative drugs addressing brain cancers. Right now, we are progressing LR 02 (a highly selective and potent ATR inhibitor with outstanding CNS penetration). With LR02 we are introducing a highly innovative therapeutic principle to beating brain cancer with a new mode of action based on synthetic lethality. Brain tumors are among the most difficult to treat and most feared forms of cancer, and it is a disease with a dismal survival rate: the average is just 15 months.

Laevoroc Immunology

is progressing LR 09 (a highly potent and selective PNP inhibitor). With LR 09 we are developing a novel molecule to guide the immune system by receptor activation to eradicate relapsed leukemia after allogeneic stem cell transplantation. Our vision is to enable the cure of this disease, which is catastrophic medically after relapse. Relapse post transplantation is the most frequent cause of treatment failure, in children and adults. Our innovation is a game-changing new therapy with the potential to become standard of care.

space
Laevoroc Chemotherapy

a joint venture with Lipomed AG, is progressing LR 06B (a patented oral gemcitabine prodrug for maintenance therapy in pancreatic, ovarian and breast cancers). Intersecting cutting-edge medicinal chemistry and formulation technology, LR 06B is rationally designed to release gemcitabine in the liver after first-pass metabolism. The innovation of our new molecule for oral administration aims to deliver a cancer therapy that provides a low healthcare system and patient burden, while allowing entirely new uses of gemcitabine, including combination therapy with oral targeted agents such as PARP inhibitors.

Laevoroc Neuro-Oncology

is the core of our company and will build a pipeline of innovative drugs addressing brain cancers. Right now, we are progressing LR 02 (a highly selective and potent ATR inhibitor with outstanding CNS penetration). With LR 02 we are introducing a highly innovative therapeutic principle to beating brain cancer with a new mode of action based on synthetic lethality. Brain tumors are among the most difficult to treat and most feared forms of cancer, and it is a disease with a dismal survival rate: the average is just 15 months.

Our company was founded in 2019, initially as TNT Medical, by Thomas Mehrling MD PhD, and Davide Guggi PhD, who have over 40 years combined experience in oncology and the pharma industry.
Our company was founded in 2019, initially as TNT Medical, by Thomas Mehrling MD PhD, and Davide Guggi PhD, who have over 40 years combined experience in oncology and the pharma industry.
Davide Guggi, PhD                                                      CSO and Co-Founder

Entrepreneur and former head of business unit at Mundipharma AT; CMC expert and QP with over 15 years’ experience in oncology drug development.
Thomas Mehrling, MD, PhD      CEO and Founder

Entrepreneur and former CEO of Mundipharma EDO, with over 20 years’ experience in oncology drug development.

Thomas Mehrling, MD, PhD
CEO and Founder

Entrepreneur and former CEO of Mundipharma EDO, with over 20 years’ experience in oncology drug development

Davide Guggi, PhD
CSO and Co-Founder

Entrepreneur and former head of business unit at Mundipharma AT; CMC expert and a QP, with over 15 years’ experience in oncology drug development.
Thomas Mehrling, MD, PhD
CEO and Founder
Entrepreneur and former CEO of Mundipharma EDO, with over 20 years’ experience in oncology drug development.
Davide Guggi, PhD
CSO and Co-Founder
Entrepreneur and former head of business unit at Mundipharma AT; CMC expert and QP with over 15 years’ experience in oncology drug development.

Other Key Team Members Include:

     Shanta Bantia,  PhD

CSO, Laevoroc Immunology

Entrepreneur, founder and CEO of Nitor Therapeutics, with over 20 years’ experience in the pharmaceutical industry.

Steve Engen, MBA

 

Business Development
Strategic Advisor

Entrepreneur with over 20 years’ experience in the biopharma industry and business development, with a focus on East Asia.

Jessica Kourniakti, DPhil

COO, Laevoroc Oncology

Entrepreneur, owner and CEO of Manage Mind AG, with over 6 years’ experience leading operations and communications projects.

Shanta Bantia, PhD – CSO, Laevoroc Immunology

Entrepreneur, founder and CEO of Nitor Therapeutics, with over 20 years’ experience in the pharmaceutical industry.

Steve Engen, MBA – Business Development Strategic Advisor

 

Entrepreneur with over 20 years’ experience in the biopharma industry and business development, with a focus on East Asia.

Jessica Kourniakti, DPhil – COO, Laevoroc Oncology

Entrepreneur, owner and CEO of Manage Mind AG, with over 6 years’ experience leading operations and communications projects.

PARTNERS

Academic Partners

Business Partners

Outsourced Partners

NEWS & EVENTS

Highlights

banner 1 (1)

03/04/2023 — Biopharma Dealmakers feature on PNP Inhibitor LR 09 (Ulodesine), a potential game-changer in leukemia treatment 

Read more

News and events

MORE NEWS

Highlights

banner 1 (1)

03/04/2023 — Biopharma Dealmakers feature on PNP Inhibitor LR 09 (Ulodesine), a potential game-changer in leukemia treatment 

Read more

News and events

MORE NEWS

Highlights

News and events

MORE NEWS